Member Info for Mafuta

RNS are factual not promotional ...

Results Inhaled NXP002 was wel tolerated, with no inflammatory response observed. Dose-dependent increases of NXP002 in lung tissue and BAL were observed, equivalent to or higher than following oral administration despite lower plasma levels. Inhaled NXP002 resulted in a dose-dependent decrease in LPS-induced BAL cell count, which was less than that seen folowing oral delivery. Despite this, inhaled delivery resulted in a greater reduction in LPS-induced BAL mediators, including MCP-1 and TGFß. This study demonstrates that inhaled NXP002 is well tolerated. Inhaled delivery has a superior effect on fibrosis related mediators whilst having a reduced systemic exposure than oral dosing.

Now someone has to sit up and notice. LH&K Mafuta

Although saying that a 20K trade went in at 12:36 at 176.48 and looks like a buy??

Warty ... I agree ... the volumes are far too small for this to be the result of sustained buying, so most likely MM's playing games again ... however as the saying goes: "every little helps" ... LH&K Mafuta

"Please note that our model is to license at the pre-clinical or early clinical stage."

Utah it's past your bedtime mate ... I said enough in my previous post if you bothered to read it ... Get some sleep you'll feel better in the morning ... but somehow I doubt that ... Over and out.

Who left the gate open?

WIP spot on ... GSK know exactly what 737 can do and it's potential worth ... And they will show their hand eventually ... and don't forget our bod have history with GSK ... They also know what other gems we have ... The deal of the century is being set up ... Just be patient and it will all come to fruition ... LH&K Mafuta

The good news keeps coming ... :0)

Zzzzzzzzzzz ... sorry but I find some of the arguments quite boring ... :0/

Yep looks like it ... Quite a number of "unknown" trades too ... Never seen this behaviour for TRX before but I believe it bodes very well for us

Mr Sneller is showing continuing interest in TRX and that is a really positive sign ... Let's see how the market responds tomorrow ... LH&K Mafuta

Good news which should prove positive for us

6th noticed that myself ... wish they would stop hanging about with SAR

GSK has acquired 100% of the outstanding shares of Affinivax. The acquisition comprised an upfront payment of $2.1 billion paid upon closing and two potential milestone payments of $0.6 billion to be paid upon the achievement of certain paediatric clinical development milestones.

When is our turn?

https://twitter.com/PeerView/status/1557517570873430018?t=OBb_IC0G9Yl9kKUBFIgpjA&s=19

Over 50 million in the space of an hour ... Probably a TR1 may be issued tomorrow ...

For today's rise ... Did I miss something?

HBomb yes he did ... Noticed that with interest

https://twitter.com/HardmanandCo/status/1557381366009954304

LH&K Mafuta